Collaborations

ICOS inks exclusive collaboration for antibody therapeutics

Published in Gene Therapy Weekly, July 8th, 2004

ICOS Corp. (ICOS) and Raven biotechnologies, inc., announced that they have entered into an agreement that provides ICOS with an exclusive option to license five of Raven's monoclonal antibody candidates for potential therapeutic applications, including cancer therapies.

Under the agreement, Raven will receive an upfront payment and potential future milestone and royalty payments. Further terms of the agreement were not disclosed.

"We have been impressed with the discoveries that Raven has made using their proprietary technologies," stated W. Michael Gallatin, PhD, ICOS vice president and scientific director. "This collaboration expands ICOS'...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-07-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry